Trending

clinical trial

Eye on ESMO: Day 2 – gamechangers take centre stage

Eye on ESMO: Day 2 – gamechangers take centre stage

Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise

X

Eye on ESMO: Day 2 – gamechangers take centre stage

https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/

Eye on ESMO 2016

Eye on ESMO 2016

The largest dedicated oncology conference in Europe, ESMO 2016, takes place 7-11 October.pharmaphorum was onsite and in conjunction

X

Eye on ESMO 2016

https://pharmaphorum.com/views-and-analysis/eye-on-esmo-2016/

VIDEO: Streamlining the process of patient enrollment

VIDEO: Streamlining the process of patient enrollment

Ever more-specific cancer medicines carry the advantage of more personalised treatments for those with the disease. At the

X

VIDEO: Streamlining the process of patient enrollment

https://pharmaphorum.com/partner-content-patients/streamlining-process-patient-enrolment/

Ideathon finalists look to the future

Ideathon finalists look to the future

Winners plan to build a corporate social responsibility programme around clinical trial recruitment.

X

Ideathon finalists look to the future

https://pharmaphorum.com/views-and-analysis/ideathon-finalists-look-future/

VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution?

VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution?

The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking

X

VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution?

https://pharmaphorum.com/partner-content-oncology/immuno-pet-offer-solution-effective-immunotherapy-monitoring/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com